Source: 55 subreddits, ~1,375 posts from /home/pengacau/torrent-downloader/reddit-scrape-2026-03-23/
Framework: Paleologo (Elements of Quantitative Investing) Ch. 8, 13.3, Sec 1.4 + ACE Playbook
Pipeline: 3-stage (shr-026/tool-006): Extract → Read theses → Verify with stock-data-analyst agents
Result: Zero actionable opportunities. shr-026 validated for third consecutive scrape.
Ch. 8 (Rademacher Complexity / Data Snooping): Screening ~1,200 tickers from 55 subreddits is equivalent to testing hundreds of strategies. Per Paleologo Table 8.1: with T=1250 and p=500, 19% pass significance by pure chance. The top-ranked ticker is likely the maximum of random noise, not signal.
Ch. 13.3 (Fractional Kelly / Parameter Uncertainty): Even if a Reddit thesis has positive EV, parameter uncertainty from social media sourcing (unknown true p, r_w, r_l) pushes Kelly fraction toward zero. Per the book's proof: x*_uncert < x* always, and for Reddit-sourced theses τ >> σ.
Section 1.4 (Sources of Excess Returns): The only legitimate edge from Reddit screening is surfacing micro-cap names where informational inefficiency exists due to no analyst coverage. The alpha comes from our verification, not their thesis.
| Rank | Ticker | $Mentions | Subreddits | Thesis Type |
|---|---|---|---|---|
| 1 | JAGU | 52 | 10 | Uranium/REE junior miner |
| 2 | EVGN | 9 | 7 | AI ag-bio, conference catalyst (Mar 24) |
| 3 | ANNA | 7 | 4 | European nat gas (Iran-Qatar) |
| 4 | TNXP | 4 | 1 | Fibromyalgia drug launch squeeze |
| 5 | USEG | — | 2 | Oil/helium value play |
| 6 | ONDS | 2 | 2 | Palantir partnership + squeeze |
| 7 | RILY | 2 | 2 | SqueezeFinder recurring |
| 8 | SLS | 3 | 2 | Existing position — short thesis posted |
Paid IR campaign for a 3-employee, zero-revenue exploration shell.
| Reddit Claim | Reality | Verdict |
|---|---|---|
| IPO at $4.00 | True. Feb 9, 2026. Now $1.55 (−61% in 6 weeks) | Accurate but misleading |
| ~5.5M public float | True. But 14.6M restricted shares unlock ~Aug 2026 (2.6x float overhang) | Misleading framing |
| IsoEnergy bought 253K shares at $4 | Technically true. But IsoEnergy is a RELATED PARTY — they sold these assets to JAGU via 2024 SPA. Not arms-length conviction. | Misleading |
| Cash for 2 years, no dilution | Company claim only, not audited. Net loss jumped 62x in 2024. | Unverified |
| Short squeeze potential | Short interest: 0.08%. DTC: 0.02 days. Zero squeeze mechanics. | FALSE |
Kill signals:
Most fraudulently represented stock in the scrape. Nearly every claim materially false.
| Reddit Claim | Reality | Verdict |
|---|---|---|
| Total Cash: $15.44M | $429K as of Q4 2025. Emergency $8.8M offering at $1.00 on Mar 9-10 (trading halted). | FALSE |
| Price target $9, 9X profits | TTM net loss: -$14.4M. Never profitable. No analyst PTs. | FALSE |
| Very good cash position | $429K cash vs -$7.1M annual burn. Weeks of cash before emergency offering. | FALSE |
| Stable growth | Revenue collapsed 64.3% YoY ($20.6M → $7.4M). Declining every quarter. | FALSE |
| $1 price support for 3 years | 30 of last 90 trading days closed below $1.00. Low: $0.87. | FALSE |
| Helium business | Zero revenue from helium. Construction hasn't started (FID March 18). | Misleading |
Kill signals:
Conference presentation Mar 24 at BIO-Europe Spring. Per shr-029: conference posters with already-published data are NOT binary catalysts and should not be sized as such. Cross-posted to 7 subreddits with identical copy (coordinated promotion pattern). "14.9 months of cash left" at $2.85M quarterly burn is a going-concern risk, not bullish. Google Cloud "collaboration" is a services agreement, not a product deal.
Real drug, but structural dilution machine overwhelms the thesis.
| Reddit Claim | Reality | Verdict |
|---|---|---|
| First new FM drug in 15+ years | True. FDA approved Aug 15, 2025. First since 2009 Savella. | Accurate |
| 4,200 scripts, 2,500 patients | True per company Q4 2025 release. But INCLUDES bridge prescriptions (don't generate revenue). | Accurate with caveat |
| $4M February sales | No public data supports this. Inconsistent with $1.4M total Tonmya revenue for 6 weeks. | Unverifiable / likely false |
| UHC market access wins | Not confirmed in any public filing. | Not confirmed |
| $50-$75 bull case, $90 blue sky | Noble Capital at $70 (only current active target). Only 3 analysts total. No $90 target. | Partially accurate |
| Short squeeze potential | SI 16.4% (below 20% threshold). $400M ATM = 199% of market cap. DTC 5.55. | FAIL per shr-021 |
Kill signals:
One bullish signal: CEO Lederman bought $223K on Mar 18 at $14.89 (open-market, own money). Per shr-002 this is meaningful, but overwhelmed by structural headwinds.
Real contracts, but extreme valuation with all insiders selling.
| Item | Value |
|---|---|
| Price | $10.08 |
| Market cap | $4.67B |
| TTM Revenue | $24.7M (189x revenue multiple) |
| 2026 Guidance | $170-180M (contingent on Mistral closing) |
| Short % float | 35.25% |
| Days to cover | 1.88 (FAIL per shr-021: <3) |
| Float | 365.8M (FAIL per shr-021: >300M) |
| Analyst PT mean | $18.38 (8 analysts, all Buy/Strong Buy) |
Kill signals:
Geopolitical spike, not a trade. Insiders selling into the move.
Genuine distressed turnaround, but requires specialist framework.
| Item | Value |
|---|---|
| Price | $7.09 |
| Market cap | $247M |
| FY2025 preliminary EPS | $9.60-$9.86 (0.74x P/E — but includes asset sale proceeds) |
| FY2024 net income | -$764M |
| Total debt | $1.44B (down from $2.45B) |
| Common equity (2024) | Negative (-$488M) |
| Short % float | 24.98%, DTC 7.76 (passes shr-021 filters) |
| Shorts trend | Covering (5.35M → from 6.04M) — not trapped |
| Insider buying | None. Compensation grants only. |
Bear thesis: Brian Kahn / Prophecy fraud exposure, Wolfpack short report, class actions, near-delisting (resolved), 2028 debt maturities as next wall. Bull thesis: Massive deleveraging, preliminary $9.60 EPS, $96M notes redeemed. Per Ch. 13.3: Parameter uncertainty about terminal outcome (solvency vs restructuring vs fraud) dominates. Specialist distressed-credit play, not Graham equity.
Position: 100 shares @ $3.90 (free-carried). Current: $4.76 (+22%).
| Item | Value |
|---|---|
| Cash (pro forma) | $114.4M ($71.8M + $42.6M Q1 warrant exercises) |
| Runway | ~3.7 years at $7.7M/quarter burn |
| REGAL events | 72/80 — final readout imminent (8 deaths needed) |
| Short interest | 29% of float, DTC 8.42, growing +18.9% MoM |
| $150M ATM | Filed Mar 20 (caused -8.5% drop). Headwind but ensures SLS009 funding. |
| Institutional | Vanguard 5.9%, BlackRock 5.3%, Millennium, Two Sigma |
| Analyst consensus | 6/7 Buy or Strong Buy |
Markovics bear thesis: Control arm assumed mOS of 8.0 months may be too low due to venetoclax improving real-world survival in CR2 AML. If control mOS is 14-18 months, trial can't hit HR of 0.636.
Chaotropy rebuttal: Historical CR2 mOS benchmarks 5.4-8.0 months. Venetoclax faces reimbursement barriers in ~50% of enrollment sites. No controlled evidence venetoclax maintenance improves OS in CR2.
IDMC continuation at 60+ events rules out extreme futility (O'Brien-Fleming) but doesn't confirm success.
Recommendation: Hold free-carry. Capital at risk is zero. REGAL readout imminent. If positive: sell in thirds per shr-016/shr-027. If negative: exit per shr-030. $114M cash means SLS009 pipeline has value even on REGAL failure.
shr-026 validated for third consecutive scrape. Every top Reddit thesis had material misrepresentations when verified against actual data. False positive rate remains ~100%.
Paleologo Ch. 8 applies directly: The data-snooping haircut for screening 1,200+ tickers from social media makes any "best" pick statistically unreliable. JAGU (top-ranked, 52 mentions, 10 subs) turned out to be a paid promotion campaign.
Ch. 13.3 (parameter uncertainty): Even the two most interesting candidates (TNXP, RILY) have τ so high that fractional Kelly rounds to zero until hard data (Q1 2026 earnings) reduces uncertainty.
Only actionable output: SLS free-carry confirmed healthy. RILY flagged for future deep dive if filing compliance stabilizes. TNXP worth monitoring for actual net revenue data post-Q1 2026.